Dr. Pooja Agarwal, Dr. Snehal Chaudhari, Dr. Amit Mistry


INTRODUCTION: Disabling pansclerotic morphea (DPM) of childhood is a rare generalized type of localized scleroderma (LS) known to follow an aggressive course with pansclerotic lesions leading to severe joint contractures and consequent immobility. It is a chronic disease of unknown etiology, seen mostly in children less than fourteen years, involving sclerosis of all the layers of skin extending rapidly through the dermis and subcutaneous tissue to involve muscle, tendon and bone. It is distinguished from generalized scleroderma by its lack of systemic involvement. Mortality is due to complications of the disease such as bronchopneumonia, sepsis or gangrene.  There is no specific laboratory finding. Treatment protocols are still evolving.

CASE REPORT: 14 years old boy presented with chief complains of tightness of the skin involving all the four limbs and trunk since 1 year. There was no history of Raynaud’s phenomenon, or exposure to chemicals and dyspnea or dysphagia. On examination multiple sclerotic plaques with atrophy present on the trunk and all four limbs and a single non- healing, painful ulcer on the left foot and distal left leg.  Skin biopsy showed thickening & homogenization of collagen bundles in dermis and subcutaneous issue. He was treated with oral steroids & methotrexate without any significant benefit.

CONCLUSION: Disabling pansclerotic morphea of childhood is exceedingly rare and severe form of Morphea. It can be very disabling and sometimes fatal. Treatment continues to present a therapeutic dilemma with only sporadic remission despite multimodality therapy. Early diagnosis is essential for initiation of proper therapy. An interdisciplinary approach is indispensable for proper management.


Disabling pansclerotic morphea of childhood, localized scleroderma, Dexamethasone pulse therapy, Methotrexate

Full Text:



Black CM. Scleroderma and fasciitis in children. Curr Opin Rheumatol 1995;7:442-8.

Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc Nov 1995; 70(11):1068-76.

PubMed. J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S115-9.

(Stucker et al,. 1999). Ref: Stucker, M., Schreiber, D., Gruss, C. Freitag, M., von Kobyeletzki, G., Kerscher, M. Severe course of a mutilating pansclerotic circumscribed scleroderma in childhood. Clinical aspects and therapy. Hautarzt, 0(2), 131-13. Medicaltalk.org.

Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980;116:169-73.

Pediatric Dermatology, vol. 19, Issue 2, pg. 151, March/April 2002.

A.R. Cantwell Jr, J. E. Jones and D. W. Kelso, Archives of Dermatology, Vol. 120 No. 5, May 1984

Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980; 116:169-73.

Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med Jun 1986; 104(6):849-57.

Bielsa I, Ariza A. Deep morphea.Semin Cutan Med Surg 2007 Jun;26(2):90-5.

Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res 1996; 288:358-362.

Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds. 2007 Dec; 6(4):291-8.

Schuermann H, Greither A, Hornstein O, eds. Krankheiten der Mundschleimhaut und der Lippen. 3rd ed. Munich, Germany: Urban & Schwarzenberg; 1966: 28-32.

Gottwald W. Melkersson-Rosenthal syndrome: klinik, nosologie, und therapie. Dtsch Med Wochenschr. 1976;101:338-344.

Miescher G. Über essentielle granulomatöse makrocheilie (cheilitis granulomatosa). Dermatologica 1945; 91:57- 85.

van den Hoogen FH, van den Kraan PM, Boerbooms AM, van den Berg WB, van Lier HJ, van de Putte LB, et al. Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture. Ann Rheum Dis. 1993;52:758–76. [PMCID: PMC1005174] [PubMed: 8257212].

Gruss C, Stucker M, Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M, et al. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol. 1997;136:293–4. [PubMed: 9068760].

Scharffetter-Kochanek K, Goldermann R, Lehmann P, Holzle E, Goerz G. PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol. 1995;132:830–1. [PubMed: 7772497]

Sunderkötter C, Kuhn A, Hunzelmann N, Beissert S. Phototherapy: A promising treatment option for skin sclerosis in scleroderma? Rheumatology (Oxford) 2006;45(Suppl 3:iii):52–4.

Nat Rev Rheumatol. 2009 Sep; 5(9):513-6, J Rheumatol 2006 December; 33:2538-40. Case Report, Mihailov I., Trashlieva M., Gospodinov D., Valkova S., Hajdoudova Chr., Konova E., Eur. J. Pediat. Dermatol. Vol. 9, n. 3, 1999.


  • There are currently no refbacks.